Key Takeaways from Global Perspectives on Early-Stage Investment and Partnering 2018

With over 130 Life Sciences entrepreneurs, innovators, investors and strategists in attendance, the Global Perspectives on Early-Stage Investment and Partnering summit, hosted by Novateur Ventures and Accel-Rx was recognized as a “first of its kind” event held in Vancouver on October 3, 2018. In the midst of the beautiful VanDusen Botanical Gardens, 6 expert panelists from leading Pharma and Venture Capitals, from across the US, Europe and China discussed topics pertaining to how life sciences start-ups and early-stage innovators should structure themselves to partner with big pharma or seek funding from venture capitals. Discussions revolved around the key factors that would help determine whether a funding or partnering opportunity was appropriate, at what stage, and what facts potential partners and investors would find valuable. Key Takeaways What You Need to Know About Pharma as a Partner and Investor Important to complete due diligence prior to seeking a meeting with Pharma Approach the Pharma company that is right for the product, based on: The Pharma company’s current interests (who have they been seeking to partner with, what products are they licensing, and very importantly, are they showing signs of staying in the space for the long-term 5 years or more) Identify and work with Advisors who have experience in vertical, product development and product commercialization Ensure you have data to back up your science Prove that you are actively seeking to identify weaknesses in your product, through vigorous testing Invest in building relationships with key partners Demystifying Chinese Venture Capital Presence in China is not a requirement to seek investments for Chinese VCs Seeking to invest in ventures with novel...